← Back to Search

FLT PET Imaging for Cancer

N/A
Recruiting
Led By Anthony F. Shields, MD, PhD
Research Sponsored by Barbara Ann Karmanos Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed solid tumor or hematologic malignancy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at using FLT PET imaging to help find, diagnose, and predict treatment response in cancer patients.

Who is the study for?
This trial is for patients with confirmed solid tumors or blood cancers, who are awaiting biopsy or surgery. They must be able to lie still in a PET scanner and fit within its dimensions. Pregnant or nursing women cannot participate, and those who can have children must use effective birth control.
What is being tested?
The study is examining the effectiveness of FLT PET imaging in detecting cancer and predicting treatment response. This phase I trial aims to determine how well this diagnostic procedure works for various types of cancer.
What are the potential side effects?
As this is an imaging study using FLT PET scans, side effects may include discomfort from lying still during the scan and potential allergic reactions to the tracer substance used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer was confirmed through a tissue sample.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 3'-deoxy-3'-[18F]fluorothymidineExperimental Treatment1 Intervention
The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
3'-deoxy-3'-[18F]fluorothymidine
2012
Completed Phase 1
~130

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,112,500 Total Patients Enrolled
Barbara Ann Karmanos Cancer InstituteLead Sponsor
164 Previous Clinical Trials
9,168 Total Patients Enrolled
Anthony F. Shields, MD, PhD5.01 ReviewsPrincipal Investigator - Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
1 Previous Clinical Trials
96 Total Patients Enrolled
~6 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top